Source comparison
Tesamorelin + Ipamorelin: Protocol Comparison
Primary Mechanism GHRH receptor agonism → endogenous GH pulses Ghrelin receptor agonism → selective GH release Dual-pathway activation → amplified pulsatile GH The blend produces higher peak GH levels (2.5–3× baseline vs 1.8–2.2× for monotherapy) without susta
This comparison does not assign a generated winner or score.
- Primary Mechanism
- GHRH receptor agonism → endogenous GH pulses
- Ghrelin receptor agonism → selective GH release
- Dual-pathway activation → amplified pulsatile GH
- The blend produces higher peak GH levels (2.5–3× baseline vs 1.8–2.2× for monotherapy) without sustained elevation that triggers negative feedback
- Visceral Fat Reduction (16 weeks)
- 12–18% from baseline (clinical trial data)
- 6–10% from baseline (observational studies)
- 15–22% from baseline (research protocols)
- Tesamorelin drives the fat loss; ipamorelin amplifies it through additional GH pulses
- Lean Mass Change (16 weeks)
- Maintenance to +1 kg (without resistance training)
- +0.5–1.5 kg (without resistance training)
- +1.5–2.5 kg (with structured resistance training)
- Neither peptide builds muscle without training stimulus. The blend supports hypertrophy when training provides the signal
- Cortisol/Prolactin Impact
- Minimal elevation (GHRH pathway selectivity)
- No elevation (ghrelin receptor selectivity)
- No elevation (complementary selectivity)
- This is critical. Older GH secretagogues elevated cortisol significantly, sabotaging body recomposition
- Dosing Complexity
- Once daily evening injection
- 2–3 times daily injections
- Once daily (tesamorelin) + 2–3 times daily (ipamorelin)
- The blend requires more frequent administration but the recomposition timeline justifies the inconvenience for serious protocols